Clinical outcomes, patient-reported outcomes and costs of management of pseudophakic cystoid macular oedema compared with age- and co-pathology-matched controls

Session Details

Session Title: Cataract Surgery: Complications & Management

Session Date/Time: Tuesday 17/09/2019 | 14:00-16:00

Paper Time: 14:56

Venue: Free Paper Forum: Podium 1

First Author: : H.Roberts UK

Co Author(s): :    F. Sanders   N. Gupta                          

Abstract Details

Purpose:

The study aims to assess the visual outcomes of pseudophakic cystoid macular oedema (CMO) as compared to age- and co-pathology matched controls, the costs of treatment and follow up, as well as the patient reported outcomes using the novel Cat-PROM5 questionnaire.

Setting:

West Suffolk NHS Foundation Trust, Suffolk, United Kingdom.

Methods:

52 eyes of 48 patients developed CMO over an 18-month period at West Suffolk Hospital, UK. Age and co-pathology matched patients were identified from clinical records over the same time period in a 2:1 ratio (90 eyes). Post-operative clinical outcomes were recorded including treatments received, costs of treatments and patient recorded outcome measures using the Cat-PROM5.

Results:

Patients with CMO reported a significantly worse outcome from surgery than controls. Furthermore, CMO patients had significantly worse visual acuity after surgery than controls (CMO 0.40 ±0.33, n=37; controls 0.30 ±0.33, n=61) despite there being no difference in pre-operative visual acuity. In the subgroup of patients with epiretinal membrane (ERM), notably CMO subjects had worse patient reported outcomes than controls, and none received prophylactic corticosteroid injection at surgery compared with 63.6% of controls. CMO resulted in an excess of 266 outpatient appointments, with 388 weeks of topical therapy, 18 orbital floor injections, and 6 intravitreal injections.

Conclusions:

With a case-control design, we have quantified the reduction in vision associated with CMO compared to age- and pathology- matched controls as well as patient reported outcomes and costs of follow up and treatment. Furthermore there was a retrospective association between CMO in ERM patients and not receiving intravitreal steroids at the time of cataract surgery compared with controls.

Financial Disclosure:

None